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Escherichia coli Nissle 1917 
enhances bioavailability of 
serotonin in gut tissues through 
modulation of synthesis and 
clearance
Jonathan Nzakizwanayo1, Cinzia Dedi1, Guy Standen1, Wendy M. Macfarlane1, 
Bhavik A. Patel1 & Brian V. Jones1,2
Accumulating evidence shows indigenous gut microbes can interact with the human host through 
modulation of serotonin (5-HT) signaling. Here we investigate the impact of the probiotic Escherichia 
coli Nissle 1917 (EcN) on 5-HT signalling in gut tissues. Ex-vivo mouse ileal tissue sections were 
treated with either EcN or the human gut commensal MG1655, and effects on levels of 5-HT, 
precursors, and metabolites, were evaluated using amperometry and high performance liquid 
chromatography with electrochemical detection (HPLC-EC). Exposure of tissue to EcN cells, but not 
MG1655 cells, was found to increase levels of extra-cellular 5-HT. These effects were not observed 
when tissues were treated with cell-free supernatant from bacterial cultures. In contrast, when 
supernatant recovered from untreated ileal tissue was pre-incubated with EcN, the derivative 
cell-free supernatant was able to elevate 5-HT overflow when used to treat fresh ileal tissue. 
Measurement of 5-HT precursors and metabolites indicated EcN also increases intracellular 5-HTP 
and reduces 5-HIAA. The former pointed to modulation of tryptophan hydroxylase-1 to enhance 5-HT 
synthesis, while the latter indicates an impact on clearance into enterocytes through SERT. Taken 
together, these findings show EcN is able to enhance 5-HT bioavailability in ileal tissues through 
interaction with compounds secreted from host tissues.
The human gastro-intestinal (GI) tract harbours a dense and complex microbial community, which 
undertakes a range of functions beneficial to the human host1–5. The pivotal role this gut microbiome 
is now believed to play in human health has led to a growing interest in strategies to manipulate its 
structure and function, to treat or prevent a spectrum of GI disorders. In this context much effort has 
been focused on probiotic microorganisms, defined as “live microorganisms which when administered 
in adequate amounts confer a health benefit on the host”6. Considerable evidence is now available to 
support the clinical efficacy of probiotics in treatment or prophylaxis of a range of maladies, not only 
those localised to the GI tract, but potentially also extra-intestinal disorders7–13.
Of the currently available probiotic bacteria, E. coli Nissle 1917 (EcN) is notable as the only 
Gram-negative species presently in use11. This gastroprotecitve E. coli strain (serotype O6:K5:H1) was 
first isolated from the faeces of a World War I soldier who, in contrast to others in his trench, was not 
affected by an outbreak of bacterial dysentery14. EcN now forms the active component of Mutaflor® 
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(Ardeypharm GmbH, Herdecke, Germany), a microbial probiotic drug that is marketed and used in 
several countries. Clinical trials have shown EcN to be effective for maintaining remission of ulcer-
ative colitis (UC)15–18, for stimulation of the of the immune system in premature infants19, for treat-
ment of infectious GI diseases20,21, for the relief of constipation22,11, and also treatment of Irritable Bowel 
Syndrome in some patients23. However, as with other probiotics, the mechanisms through which EcN 
exerts these beneficial effects, and interact with the human host, remain largely undefined.
An area of particular interest in this regard is the potential for probiotics to modulate synthesis, 
release, and reuptake of transmitters by epithelial endocrine cells (enterochromaffin cells, EC cells) in 
the gut. In particular, serotonin (5-Hydroxytryptamine or 5-HT) is an abundant gut associated trans-
mitter, with EC cells of the gut epithelium generating ~90% of the total 5-HT pool extant in the human 
body24,25. The synthesis of 5-HT in EC cells begins with the conversion of tryptophan to the inter-
mediate 5-hydroxytryptophan (5-HTP), catalysed by tryptophan hydroxylase-1 (Tph-1). Subsequently, 
5-HTP is converted to 5-HT through the activity of aromatic L-amino acid decarboxylase (L-AADC), 
and the newly synthesised 5-HT is stored in vesicles before release following mechanical and/or chemical 
stimulation of the mucosa25,26. The majority of 5-HT released from EC is subsequently cleared into the 
neighboring enterocytes by the serotonin transporter (SERT), and rapidly metabolised to various end 
products, of which 5-hydroxyindole acetic acid (5-HIAA) is the most abundant25,26.
In the GI tract 5-HT interacts with a variety of serotonergic receptors located on intrinsic primary 
afferent neurons (IPANs), and regulates a variety of gut functions, including gut motility, ion secretion, 
and sensory functions27–29. Through sequestration by platelets, 5-HT synthesised in the GI tract is also 
distributed systemically, and contributes to regulation of global homeostatic processes, as well as key 
aspects of human development. Among these are roles of regulation of immune responses, bone devel-
opment, and cardiac function30–33, as well as an influence on aspects of mood and behaviour13,34. In 
keeping with a crucial role in normal gut function, alterations in 5-HT signalling have been implicated 
in various diseases and disorders such as colon carcinoma, inflammatory bowel diseases (IBD), enteric 
infections, and functional disorders such as irritable bowel syndrome (IBS)35–39. Our own work has also 
recently linked alteration of 5-HT signalling with age related decline in gut function, including motility 
and the onset of chronic constipation40,41.
In terms of factors that may modulate 5-HT signalling, mounting evidence that the gut microbiome 
can modulate this pathway is of particular relevance to the development of probiotic-based interven-
tions for GI disorders13,42,43. Recent studies using animal models have demonstrated a clear impact of 
gut-associated microbes on 5-HT signalling, both in the GI tract and systemically. In particular, germ 
free animals devoid of a gut microbiome exhibit significantly altered levels of 5-HT in the brain and 
peripheral circulation, and altered turnover of 5-HT13,42–44. Furthermore, members of the gut microbiota 
related to Clostridia (a dominant family of bacteria in the gut microbiome) have been shown to modulate 
5-HT signalling through production of soluble metabolites that influence 5-HT synthesis, and through 
this mechanism, affect both GI motility as well as platelet aggregation43. Recent evidence also points to a 
role for 5-HT signalling in communication between the GI tract, the central nervous system and brain, 
and the gut microbiome (the microbiome-gut-brain axis), with manipulation of the gut microbiome 
associated with changes in aspects of host behaviour and mood through alteration of this dialogue13.
Taken together, the role of the serotonergic system in both local and systemic disease, the GI tract 
as the major site of 5-HT production in humans, and emerging evidence of gut microbiome mediated 
regulation of 5-HT bioavailability, point to manipulation of serotonergic signalling in particular as a 
prime target for development of probiotic interventions. However, relatively little is known regarding the 
impact of EcN or other species on 5-HT bioavailability or signalling in the GI tract. Therefore, the aim 
of this study was to evaluate the capacity for EcN treatment to influence regulation of the serotonergic 
system in intestinal tissues, using an ex-vivo co-culture model. In doing so we demonstrate the ability 
of EcN, but not a commensal E. coli strain (MG1655), to influence 5-HT signalling through interaction 
with, and modification of, secreted host derived factors.
Results
Effect of E. coli Nissle on 5-HT overflow. In order to assess the effect of EcN on 5-HT overflow 
from EC cells we first treated ex-vivo ileal tissue with cultures of EcN, or the gastrointestinal commensal 
E. coli MG1655 as a control, and measured extra-cellular levels of 5-HT post treatment. In tissues treated 
with EcN we observed a significant elevation in extra-cellular levels of 5-HT, compared to untreated con-
trols or MG1655 treated tissues (Fig. 1a,b). Microscopic examination of tissue treated with E. coli cultures 
confirmed that tissue remained intact and the observed elevation in 5-HT levels induced by EcN was not 
due to the disruption or degradation of the intestinal epithelium (Fig. 1c).
The role of EcN K5 capsule in 5-HT overflow. Given the distinct impacts of EcN and MG1655 on 
extra cellular 5-HT in our ex-vivo system, we next sought to understand how key differences in these 
gut-associated strains of E. coli may account for their differential effects on 5-HT overflow. Although 
structurally and biochemically similar, a major distinguishing feature of EcN and MG1655 is the com-
position of the outer polysaccharide capsule, with EcN generating a K5 type capsule compared to the 
MG1655 K12 type capsule. Since these outer surface structures are often the point of contact between 
host and bacterial cells, and in light of the established role of the EcN K5 in host-microbe interactions45,46, 
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we hypothesized that the EcN K5 capsule may play a role in the observed EcN induced elevation of 
extra-cellular 5-HT. To test this, ileal tissue was treated with isogenic EcN capsule deficient mutants, 
EcN∆kfiB and EcN∆kfiC, in which core K5 biosynthesis genes are deleted46. These experiments showed 
K5 deficient mutants were still able to induce significantly elevated levels of extracellular 5-HT, compa-
rable to those elicited by wild type EcN (Fig.  2), excluding a role of the K5 capsule in EcN mediated 
5-HT overflow.
Short chain fatty acid production is not involved in EcN mediated 5-HT overflow. Because 
the production of short chain fatty acids (SCFA) such as acetate, butyrate and propionate have been 
shown to stimulate 5-HT release in vivo47, and acetate is a key end product of E. coli growth in glucose 
containing media such as Krebs buffer, we next assessed the potential for the observed effects to be the 
result of enhanced SCFA production in EcN compared to MG1655. As expected, neither strain was able 
to generate detectable levels of butyrate or propionate, but both produced acetate under co-culture condi-
tions with intestinal tissues (Fig. 3). However, under these conditions no significant differences in acetate 
production were observed between EcN and MG1655, indicating the elevated 5-HT release instigated by 
EcN was not attributable to acetate production.
EcN modulates 5-HT overflow through interaction with secreted host-derived factors. Recent 
studies have also indicated that a range of soluble metabolites generated by gut microbes increase 5-HT 
bioavailability in murine models, and include those derived from the modification of host generated 
compounds43. Therefore, to determine if the effect of EcN on extra-cellular 5-HT was attributable to 
factors that may be secreted by EcN; the result of direct interaction of EcN cells with ileal tissues; or due 
Figure 1. Measurement of extracellular 5-HT in ileal tissues treated with E. coli Nissle 1917 and 
MG1655. Ileal tissue samples and E. coli cultures were co-incubated for 1 h at 37 °C, 5% CO2, and extra 
cellular 5-HT levels measured in real-time using electrochemical methods (amperometry). (A) Example of 
electrochemical measurements obtained during experiments and converted to uM 5-HT based on standard 
curves constructed from known 5-HT concentrations. The BDD electrode was placed 0.1 mm over tissue. 
(B) Measurements of extracellular 5-HT from treated and untreated tissue sections. In all cases levels 
are normalized to surface area of the tissue. Data shown as mean ± S.E.M. (n = 4). (C) Example images 
of treated or untreated tissue sections used in experiments demonstrating intact epithelium following 
treatment and measurements. Arrows indicated the BDD electrode, and all images are × 10 magnification. 
KB - control samples incubated with Krebs buffer only; +EcN- samples treated with E. coli Nissle 1917; 
+MG1655 - samples treated with E. coli MG1655. ***p ≤ 0.001 vs KB; ††††p ≤ 0.0001 vs MG1655.
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to the interaction of EcN with host derived factors, we next investigated the effect of a range of cell-free 
supernatants on 5-HT overflow in our ex-vivo co-culture system (Supplementary Fig. 1). These were 
derived from either: i) E. coli cultured in Krebs buffer alone (EcN-SNT); ii) Untreated ileal tissue incu-
bated in Krebs buffer only (I-SNT); iii) Supernatants from untreated ileal tissue incubated with EcN cell 
suspensions prior to exposure of fresh tissue sections with derived cell-free supernatants (I-EcN-SNT). 
I-SNT recovered from untreated ileal tissues showed no significant impact on 5-HT levels when used to 
treat fresh tissue sections. Treatment of ileal tissue with EcN-SNT also resulted in no significant alter-
ation in extra-cellular 5-HT, contrary to treatment with EcN cell suspensions (Fig.  4). However, when 
SNT recovered from ileal tissues were first incubated with EcN cells (I-EcN-SNT), before subsequent 
treatment of fresh tissue, 5-HT levels were significantly elevated (Fig. 4). These results point to an inter-
action of EcN with ileum-secreted factors to regulate 5-HT overflow in EC cells.
Figure 2. Role of E. coli Nissle 1917 K5 capsule in 5-HT overflow. The potential role of the EcN K5 
capsule in 5-HT overflow was investigated using the isogenic K5 deficient mutants EcN∆kfiB and EcN∆kfiC 
(Nzakizwanayo et al.46). Ileal tissue samples were treated with live cell suspensions and extracellular 5-HT 
levels measured using amperometry as in Fig. 1. Data shown represent means ± S.E.M. (n = 4). KB - control 
samples incubated with Krebs buffer only; EcN- samples treated with E. coli Nissle 1917; MG1655 - samples 
treated with E. coli MG1655; KfiC - samples treated with EcN∆kfiC; KfiB- samples treated with EcN∆kfiB. 
***p ≤ 0.001 vs KB; *p ≤ 0.01 vs KB.
Figure 3. Role of short chain fatty acid production in EcN mediate 5-HT overflow. To determine if the 
capacity for production of short chain fatty acids (SCFA) was enhanced in EcN compared to MG1655, and 
relevant to EcN mediated 5-HT overflow, the levels of SCFA generated by each strain during growth in 
mucosal co-culture was measured. Bacterial cell suspensions in krebs buffer with ileal mucosal scrapings 
were incubated at 37 °C with 5% CO2 for 1 h, before measurement of SCFA by HPLC. Propionate and 
butyrate were not detected in this assay but both EcN and MG1655 generate acetate as show in charts. Data 
show means ± S.E.M. (n = 3). **P ≤ 0.01 ***P ≤ 0.001 Vs KB. KB - Krebs buffer only; EcN – E. coli Nissle 
1917; MG1655 – E. coli MG1655
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Effect of E. coli Nissle on 5-HT synthesis and clearance. Because the observed effect of EcN on 
extra-cellular 5-HT may be due to action at various stages of the serotonergic system (synthesis, release, 
clearance), we next investigated the impact of EcN on the 5-HT pathway as a whole. Following EcN treat-
ment, both intracellular and extra-cellular levels of 5-HT, precursors, and metabolites were determined in 
dissociated ileal mucosa by HPLC (Fig. 5a,b). Intracellular levels of the 5-HT precursor tryptophan were 
not significantly different across the treated samples and controls (Fig. 5c). In contrast, intracellular levels 
of the tryptophan derived 5-HT intermediate, 5-Hydroxytryptophan (5-HTP), were shown to be signif-
icantly higher in tissues treated with both EcN cells and I-EcN-SNT (Fig. 5d). Commensurately, meas-
urement of total 5-HT (intra and extracellular) indicated a > 5-fold increase of 5-HT content in tissues 
treated with either EcN cells or with I-EcN-SNT, compared to untreated controls (Fig. 5e). Moreover, the 
stimulatory effect of EcN on 5-HTP and 5-HT was dose-dependent, and proportionally reduced when 
inoculum density of EcN was reduced 10-fold. The 5-HIAA content of dissociated mucosa was also sig-
nificantly altered by EcN treatment, however, in this case distinct effects were observed when tissue was 
treated with EcN cells compared with I-EcN-SNT (Fig. 5f). In tissues treated with EcN cells 5-HIAA was 
significantly decreased, however, no significant alteration in 5-HIAA levels were observed when tissues 
were treated with I-EcN-SNT (Fig. 5f). No significant effect was elicited by the commensal MG1655 on 
the levels of any compound measured.
Discussion
Recent studies have provided clear evidence that bacteria can modulate transmitter signalling in the GI 
tract, and in doing so influence local gut function, as well as aspects of systemic metabolism and poten-
tially also mood and behavior13,43,48. Collectively, these studies highlight the potential for probiotic-based 
modulation of transmitter signalling systems to help tackle a wide range of disorders13,43,48–50. In the pres-
ent study, we applied ex vivo co-culture models using murine ileum tissue, in conjunction with chemical 
and electroanalytical approaches, to determine the impact of EcN on the serotonergic system. The ex vivo 
co-culture system provides some important advantages in the initial evaluation of agents that modulate 
transmitter signaling in gut tissues. In particular, this permits the detailed and accurate measurements 
of the entire 5-HT transmission process directly in the mucosa, and in real-time, which is presently not 
possible in vivo. In contrast, the measurements of 5-HT possible during in vivo studies (from luminal or 
faecal contents) are unlikely to fully reflect the local mucosal situation, where the physiological effects 
of 5-HT are exerted and turnover takes place. The ex-vivo system allowed us to monitor both extra and 
intracellular levels of relevant metabolites directly in intact tissues, in response to defined “doses” of 
EcN, and although not without limitations (as covered in subsequent discussion), this system is generally 
considered to provide a good representation of the in vivo response.
Figure 4. EcN modulates 5-HT bioavailabiliy through interaction with secreted host derived factors. 
The effect of secreted EcN or host derived factors on 5-HT overflow was determined by measuring 5-HT 
release after treatment of tissues with various culture or co-culture supernatants (at 37 °C with 5% CO2 for 
1 h). Extracellular 5-HT was measured by amperometry as for Fig. 1. Data are means ± S.E.M. (n = 4), and 
measurements normalized to the surface area of tissue sections. KB - Krebs buffer only; +I-SNT – Tissue 
sections exposed to supernatant derived from untreated ileal tissue (incubated in Krebs buffer only); +EcN-
SNT – Tissue exposed to supernatants derived from E. coli Nissle 1917 cultures grown in Krebs buffer; +I-
EcN- SNT – Tissue exposed to supernatants from untreated ileal tissue incubated with EcN cell suspensions. 
**p ≤ 0.01 vs KB, †p ≤ 0.05 vs I-SNT, ###p ≤ 0.001 vs EcN-SNT.
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Figure 5. Neurotransmission process in ileal cells treated with E. coli Nissle 1917. To determine the 
impact of EcN treatment on the entire neurotransmission process, disaggregated intestinal villi (mucosal 
scrapings) were used to measure intracellular levels of 5-HT, precursors and metabolites following EcN 
treatment. Samples of Ileal mucosal scrapings were co-cultured with control Krebs buffer (KB), EcN 
cell suspensions (EcN), E. coli MG1655 cell suspensions (MG1655); EcN supernatants (EcN- SNT) or 
EcN modified ileal supernatants (I-EcN SNT) for 1 h at 37°C, 5% CO2, and post co-culture levels of 
neurochemicals were determined by HPLC. (A) Microscopic analysis of ileal mucosal cells after co-culture 
with live EcN, demonstrating intact villi structures post treatment. (B) Schematic of the serotonin pathway, 
highlighting major intermediates and key enzymes and transporters, in 5-HT synthesis and clearance. 
Compounds measured in these experiments are indicated by letters (C,D,E,F), and relate directly to data 
displayed in parts (C,D,E,F) of this figure. Compounds: 5HTP = 5-hydroxy-tryptophan; 5-HT = serotonin; 
5-HIAA = 5-hydroxy-3-indoleacetic acid. Enzymes & transporters: TpH-1 = Tryptophan hydroxylase, 
catalyzes conversion of tryptophan to 5-HTP; AADC = Aromatic L-amino acid decarboxylase, converts 
5-HTP to 5-HT in this pathway; SERT = Serotonin transporter, transports extra-cellular 5-HT into 
enterocytes; MAO = Monamine oxidase, catalyzes the metabolism of 5-HT to 5-HIAA in enterocytes. 
Cell types: IEC - Intestinal Epithelial Cell; EC - Enterochromaffin Cell; IPANs - Intrinsic Primary 
Afferent Neurones. (C,D,E,F) Levels of intracellular tryptophan; Intracellular 5-HTP; total intracellular 
and extracellular 5-HT; and intracellular 5-HIAA; respectively. Data are means ± S.E.M. (n = 4), and 
measurements normalized to the tissue mass by total protein. KB - Krebs buffer only; EcN – E. coli Nissle 
1917; EcN 1/10 – E. coli Nissle 1917 at 1/10 cell density of EcN; MG1655 – E. coli MG1655; EcN-SNT – 
Supernatants derived from E. coli Nissle 1917 cultures grown in krebs buffer; I-EcN- SNT – Supernatants 
from untreated ileal tissue incubated with EcN cell suspensions. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 vs KB.
www.nature.com/scientificreports/
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This revealed that EcN is able to enhance bioavailability of 5-HT in a dose-dependent (bacterial 
density) manner. Notably the levels of EcN found to induce this elevated 5-HT overflow in our study 
are comparable to those found in commercial preparations, with Mutaflor capsules containing between 
2.5 × 109–1010 cfu of viable EcN (Ardeypharm GmbH). Furthermore, our data suggested that EcN may 
modulate 5-HT signalling at multiple points in the serotonin pathway, with evidence for distinct mech-
anisms working at different stages (synthesis and clearance).
In the case of the elevated 5-HT overflow elicited by EcN, this was not attributable to direct 
host-microbe interactions, or key components of the cell surface previously implicated in EcN probi-
otic effects (the K5 capsule). Instead, EcN mediated 5-HT overflow appears to be directed primarily 
by the interaction of EcN with exogenous factors secreted from host tissues. Compounds in cell-free 
supernatants of EcN have been previously found to mediate probiotic effects such as reinforcement of 
the intestinal mucosal barrier51–53, modulation of human colonic motility54, and regulation of immune 
functions55,56. Moreover, recent studies have identified a suite of soluble bacterial metabolites, generated 
by indigenous gut microbes, that increases 5-HT synthesis in EC cells43. These include metabolites that 
may be derived from interactions with host-generated substrates such as the SCFA butyrate, propionate, 
and acetate, as well as the secondary bile acid deoxycholate. However, our findings confirm that EcN 
like other E. coli strains does not generate appreciable levels of propionate or butyrate, and comparable 
levels of acetate to the non-serotogenic E. coli MG1655 under co-culture conditions, eliminating SCFA 
production by EcN as a source of the observed 5-HT elevation.
In terms of secondary bile acid production, this activity is also believed to be largely lacking in 
E. coli, and confined to members of the Clostridiales, which is congruent with the phylogenetic affiliation 
of indigenous 5-HT modulating organisms identified in other studies43,57,58. Our own confirmatory anal-
yses suggests that both MG1655 and EcN encode genes with homology to those involved in secondary 
bile acid formation in other bacteria, albeit weak homology in most cases (Supplementary Table 1). 
Therefore, it is possible that EcN may be capable of generating secondary bile acids in our model system, 
but, it is unlikely that relevant levels of free primary bile acids (substrates for secondary BA formation) 
remain in the ex-vivo tissue sections after recovery and preparation. Furthermore, identifiable genes for 
bile acid de-conjugation (which is required before secondary bile acid formation can take place57,59), 
are absent from the EcN genome sequence (Supplementary Table 1), making secondary BA formation 
unlikely to explain our observations.
Other bacterial metabolites identified as potential regulators of 5-HT synthesis or overflow include 
tyramine, p-aminobenzoate (PABA), and α -tocopherol. Collectively the synthesis of these compounds 
are linked to the production of chorismate through the shikimate biosynthesis pathway60,61, although 
α -tocopherol is considered to be restricted to plants and photosynthetic bacteria, and therefore unlikely 
to be relevant in our experiments60. Of particular relevance to 5-HT signalling is the association of 
the shikimate pathway and chorismate biosynthesis with de novo generation of several aromatic amino 
acids, which include the tyramine precursor tyrosine, and also the 5-HT precursor tryptophan. Some 
bacterial species commonly found in the gut microbiome have also been shown to possess tryptophan 
decarboxylase activity and to generate the serotonergic potentiator tryptamine, which is known to induce 
5-HT release from EC cells62. Tyramine is also a biogenic amine formed through the decarboxylation 
of the amino acid tyrosine, and can act as a neurotransmitter and stimulates chatecholamine release, 
influencing gut motility43,63.
Taken together, these observations afford the potential for a direct impact on 5-HT signalling through 
microbially derived tryptamine as well as tyramine. However, the lack of activity from EcN culture super-
natants argues against the production of tryptamine and tyramine (at least at levels sufficient to influ-
ence 5-HT overflow), and available evidence supports a lack of tyrosine decarboxylase activity among 
E. coli species in general62. Our own survey of both EcN and MG1655 genome sequences, using recently 
described bacterial tryptophan decarboxylases of proven function62, did identify genes with weak homol-
ogy to the C. sporogenes tryptophan decarboxylase in both strains (Supplementary Table 2). Despite this, 
the divergent impacts of MG1655 and EcN on 5-HT overflow do not support tryptamine production as 
responsible for the enhanced 5-HT bioavailability generated by EcN treatment.
Conversely, the production of folate is an essential biosynthetic pathway in E. coli and other bacteria, 
and bacteria in the gut are responsible for the generation of a significant fraction of the folate required 
by humans61,64. PABA is a key intermediate in this pathway, and although there is currently no clear 
physiological role for PABA in regulation of gut function or homeostasis, a possible impact on 5-HT 
bioavailability has been documented43,64. However, the lack of this pathway and production of the major-
ity of precursors in mammals, along with the lack of 5-HT modulation exhibited by E. coli MG1655 in 
our experiments, would also cast doubt on changes in folate biosynthesis and generation of PABA as 
responsible for the observed impact of EcN on 5-HT bioavailability. This would require interaction with 
host-derived factors to influence folate biosynthesis in EcN but not MG1655, which remains a possible, 
if unlikely, explanation for the observed 5-HT modulation by EcN.
Taken together, our data clearly indicates that interaction between secreted host factors and EcN is 
required to generate the observed effects on 5-HT overflow, but provides little evidence to support the 
involvement of bacterial metabolites previously documented to influence 5-HT bioavailability (SCFA, 
secondary bile acids, tyramine, tryptamine, PABA, α -tocopherol)43, and the exact nature of this sig-
nal remains to be determined. Nevertheless, our results do indicate that the basic mechanism through 
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which 5-HT levels are elevated is similar to that described for bacteria in recent studies43. Formation 
of the 5-HT precursor 5-HTP is catalysed by Tph-1, which converts tryptophan to 5-HTP, and is the 
rate-limiting step in 5-HT synthesis and turnover in gut tissues65–67. Our analysis of EcN impact on the 
overall serotonin circuit, through measurement of the major precursors and metabolites, showed that 
EcN was able to increase the levels of intracellular 5-HTP in a dose dependant manner (in contrast to 
the commensal E. coli MG1655). This points to an increase in Tph-1 activity in EcN treated tissues, ulti-
mately leading to an increase in 5-HT synthesis, which has also been reported as the mechanism through 
which members of the indigenous gut microbiome increase 5-HT bioavailability43.
It is also notable that no significant differences in background tryptophan levels were observed in 
these experiments. Because tryptophan is the substrate for Tph-1, an increase in the activity of this 
enzyme and the wider 5-HT synthesis machinery, would be expected to lead to a commensurate reduc-
tion in background levels of tryptophan. This is supported by observations of elevated background tryp-
tophan levels in serum and faeces of germ free animals where 5-HT synthesis is reduced43, and such 
changes in tryptophan concentration could be expected to be more pronounced in the closed ex-vivo 
system we have utilised in this study.
In contrast, our data appear more in keeping with conflicting reports of the relationship between 
tryptophan concentration and 5-HT synthesis, which describe elevated levels of tryptophan in plasma 
of germ free animals when 5-HT levels are also elevated in various tissues13,44. The ability of E. coli to 
synthesise tryptophan de novo may in part explain the stability of levels observed in our ex-vivo models, 
by offsetting increased utilisation when 5-HT synthesis is enhanced. However, since elevated 5-HTP was 
not observed for MG1655 treated tissues, despite comparable levels of tryptophan being detected in these 
experiments, it is unlikely that this explanation fully accounts for our observations, if at all, and further 
work will be required to understand the exact factors leading to the stability of tryptophan levels in our 
experiments, and also if this translates to the in vivo setting.
Our data also point to effects of EcN on 5-HT clearance. Typically, extra cellular 5-HT released 
into the lumen is cleared by uptake into enterocytes via the serotonin transporter SERT, and converted 
into the major metabolite 5-HIAA by the action of monoamine oxidase25,26. This continual clearance 
is required for completion of the serotonin circuit and termination of the biological effects of released 
5-HT. In treatments that elevate extracellular 5-HT, we would therefore predict commensurate increases 
in levels of 5-HIAA. However, in tissues treated with EcN cells levels of 5-HIAA were significantly 
reduced (indicating reduced 5-HT clearance), while I-EcN-SNT treated tissues showed no significant 
difference in 5-HIAA compared to untreated controls.
The lack of significant changes to 5-HIAA in I-EcN-SNT treated tissues, despite elevated 5-HT levels, 
may have several explanations. These include the potential for the total 5-HT measured in these experi-
ments to primarily reflect intracellular 5-HT, a saturation of SERT activity effectively limiting the rate of 
clearance, or an inhibitory effect on 5-HT uptake by SERT (again restricting the maximal level of clear-
ance observed). The latter scenario is also congruent with the significant reduction in 5-HIAA observed 
in tissue sections treated with EcN cells (since supernatants will also contain cellular debris including 
cell envelope components), but suggests that cell-cell interaction is required for EcN to fully exert these 
effects, and raises the potential for a direct interaction and interference with SERT. Conversely, it is pos-
sible that EcN is able to modulate the activity of monoamine oxidase (MAO) to reduce the formation 
of 5-HIAA. Nonetheless, the intracellular location of MAO coupled with the significant reduction of 
5-HIAA by EcN cells specifically, would suggest interaction between EcN and surface associated proteins 
such as SERT to be a more likely scenario.
In summary, our data highlight the ability of EcN to increase the bioavailability of 5-HT in intestinal 
tissues, via modulation of several distinct aspects of the serotonergic system (synthesis and clearance). 
These findings may have important implications for the role of probiotics such as EcN in the manage-
ment of intestinal disorders, and the broader range of extra-cellular maladies in which 5-HT signaling 
plays a role. Notably, the potential increase in 5-HT afforded by EcN and potential impact on SERT 
are of interest in light of the long history of using selective serotonin reuptake inhibitors to treat mood 
disorders. This is particularly pertinent with the emerging role of the gut microbiome in homeostasis of 
the gut-brain-microbiome axis, and the potential for probiotic manipulation of this community to play 
an important role in the future treatment of mood disorders13,48.
In addition, studies of patients with constipation predominant IBS (IBS-c) have pointed to reductions 
in EC cell number and 5-HT production in gut tissues. This is hypothesized to perturb communica-
tion with the enteric nervous system, reducing intestinal motility and leading to constipation36,68. As 
such EcN mediated elevation of mucosal 5-HT could have therapeutic benefit in management of IBS-c, 
or other functional disorders where 5-HT reduction is implicated. On the contrary, conditions where 
elevated 5-HT has been linked to disease pathology, such as some types of IBD associated with loss or 
inactivity of SERT69, there may be potential for EcN administration to exacerbate the underlying disease 
state, highlighting the need for a clear understanding of host-probiotic interactions to ensure the most 
appropriate and effective use of probiotics. Notable in this context are the lack of effects we observed 
in experiments with the well characterised gut commensal E. coli MG165570 pointing to modulation of 
5-HT as a specific “probiotic” trait of EcN rather than a property of gut-associated E. coli in general.
Finally, although a powerful approach, the ex-vivo co-culture system used here is not without limita-
tions, which should be kept in mind when interpreting these data, and particularly when considering any 
www.nature.com/scientificreports/
9Scientific RepoRts | 5:17324 | DOI: 10.1038/srep17324
possible impact on host health. Perhaps of most importance is the likely perturbation of the intestinal 
microbiota and luminal milieu in the ex-vivo system, both of which may contribute to regulation of gut 
transmitter systems and influence the response to treatments with agents such as EcN. The wider impact 
of EcN 5-HT modulation on host health will clearly require the conduct of carefully controlled in vivo 
studies, including those evaluating long-term impact of 5-HT modulation, and the data presented here 
should now provide a sound platform to facilitate the design of these subsequent investigations.
Materials and Methods
Bacterial strains and cultures. E. coli Nissle 1917 (EcN; Ardeypharm GmbH, Herdecke, Germany), 
its K5 capsule mutants, EcN∆kfiB and EcN∆kfiC46, and E. Coli K12 strain MG1655 (CGSC7740)70 were 
used in this study. All strains were routinely grown in Lauria-Bertani (LB) broth (Fisher Scientific, UK) 
overnight at 37 °C with shaking (150 rpm). Cells were harvested by centrifugation, re-suspended in sterile 
Krebs buffer solution pH 7.4 (mM: 117 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgCl2, 1.2 NaH2PO4, 25 NaHCO3, 
and 11 glucose) and used in co-cultures in a final concentration of 2 × 109 Cfu/mL (EcN) or 2 × 108 Cfu/
mL (EcN 1/10).
Collection of intestinal tissue. All tissue samples used in this study were obtained from 
three-month-old male C57BL/6 mice. All procedures were carried out according to U.K. Home Office 
regulations and were approved by the University of Brighton Ethics Committee. Mice were euthanized 
via CO2 then cervical dislocation, the abdomen was subsequently opened and intestines removed. A 
section of the distal ileum (2 cm from caecum) was dissected and placed in ice-cold oxygenated (95%, 
O2, 5% CO2) Krebs buffer solution pH 7.4.
Ileal tissue preparation for measurement of serotonin and neurotransmission processes. Two 
protocols were utilised in order to investigate the influence of EcN on extracellular 5-HT and intracel-
lular precursors and metabolites, as previously described by Lwin & Patel71 and Parmar et al.72. For 
both protocols, ileal sections were initially divided into 1 cm long segments, transferred to an inverted 
pre-chilled glass Petri dish, opened longitudinally along the mesenteric border, and laid out with the 
mucosal surface facing up giving ~1 cm2 segments. The flattened tissue was subsequently rinsed twice 
with Krebs buffer solution to remove any visible faecal matter.
For measurement of extracellular 5-HT using amperometry, rinsed tissue segments were transferred 
to a 6-well plate, each well containing 2 mL ice-cold oxygenated Krebs solution for further co-culture 
experiments. For intracellular monitoring of 5-HT precursors and metabolites, rinsed tissue segments 
were gently scrapped to remove the mucosal layer using a scalpel. The resulting tissue scrapings were 
transferred to a chilled 1.5 mL- Eppendorf tube and gently aggregated using a plastic microfuge pestle to 
get individual villi disaggregated from the supporting connective tissue. This suspension was then vortex 
for 1 min and fractions were transferred to a 6-well plate for further co-culture experiments.
Preparation of cell free supernatants. An overview of cell free supernatants utilised in this study 
is provided in Supplementary Fig. 1. EcN Supernatants (EcN-SNT): Supernatants derived solely from 
E. coli Nissle 1917 cultures (EcN-SNT) were obtained by recovery of EcN cultures from LB broth cultures 
by centrifugation, washing of recovered cells with PBS, and re-suspension at 2 × 109 Cfu/mL in Krebs 
buffer. These cell suspensions were incubated at 37 °C, 5% CO2 for 1 h. Supernatants were then collected 
by centrifugation (13,000 g, 5 min) and filtration using a Whatman 0.45 μ m pore-size filter, before use 
directly in experiments. Ileum Supernatants (I-SNT): Supernatants obtained from untreated ileum sec-
tions were recovered following incubation of tissue in Krebs buffer (37 °C, 5% CO2 for 1 h), followed 
by centrifugation and filtration as above. Ileum EcN modified Supernatants (I-EcN-SNT): To obtain 
supernatants exposed to both Ileum and EcN cells independently, EcN cells recovered from LB broth 
cultures were suspended in I-SNT preparations described above to a final density of 2 × 109 Cfu/mL, 
and incubated for a further hour (37 °C, 5% CO2). The resulting ileum-EcN-SNT was recovered by cen-
trifugation and filtration as above, before use in further experiments.
Amperometric measurement of extracellular 5-HT in co-culture experiments. Oxygenated 
ileal tissues were co-incubated with E. coli cell suspensions (in Krebs buffer at 2 × 109 Cfu/mL) or cell 
free supernatants (see above) in 6-well plates. Co-cultures were incubated for 1 h at 37 °C, 5% CO2, and 
controls included ileal sections with Krebs buffer only. After co-incubation, tissue samples were pinned 
in a Sylgard® (Dow Corning, UK) lined Teflon recording chamber and perfused with warm (37 °C) 
Krebs solution at a flow rate of 2 mL/min. Tissues were perfused for 10 min prior to commencing a 
series of measurements. For continuous amperometric recordings of 5-HT overflow, measurements were 
carried out using a BioStat™ multi-channel potentiostat (ESA Biosciences, Inc, USA). A three-electrode 
system was utilised with a stainless steel auxiliary electrode, a Ag|AgCl (3 M KCl) reference electrode, 
and a 76 μ m boron-doped diamond (BDD) electrode which served as the working electrode. The BDD 
microelectrode potential was held over the tissue at + 650 mV vs Ag|AgCl which was sufficient to oxidize 
serotonin at a mass transfer limited rate73,74. Using a micromanipulator, the BDD microelectrode was 
positioned several centimetres away from the mucosa for several seconds for background recordings. 
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For recordings from tissues sections, the electrode was positioned 0.1 mm over the tissue for 20 s, where 
reproducible oxidation currents were recorded. This procedure was repeated 5 times for each tissue.
HPLC measurement of 5-HT and intermediates in co-culture experiments. Mucosal scrapings 
were inoculated with EcN cell suspensions (at 2 × 109 Cfu/mL in 250 μ L final volume Krebs buffer) or 
supernatants (see above) in 12-well plates then incubated for 1 h at 37 °C, 5% CO2. Controls included 
mucosal scrapings with Krebs buffer only, as well as EcN in Krebs buffer without addition of mucosal scrap-
ings. After co-incubation, samples were immediately transferred to prechilled 1.5 mL sterile Eppendorf 
tubes and homogenised in 250 μ L of ice-cold 0.1 M HClO4 by vortexing. The samples were then cen-
trifuged at 13,000 g for 10 min at 4 °C and the resultant supernatant was analysed for 5-HT, its precur-
sors and metabolites, using HPLC with Electrochemical Detection ED as described by Parmar et al.72. 
The HPLC apparatus consisted of a Jasco HPLC pump (Model: PU-980) and Rheodyne manual injec-
tor equipped with a 20 μ l loop. A Kinetic® ODS 2.6 μ m 150 mm × 4.6 mm i.d. analytical column with 
a guard column (Phenomenex®, Macclesfield, UK) was employed. The HPLC system was run at a flow 
rate of 1.0 mL min−1. CHI630B potentiostat (CH Instruments, Austin, TX, USA) was used to control 
the detector voltage and record the current. A 3 mm glassy carbon electrode (flow cell, BAS) served as 
the working electrode and was used with a Ag|AgCl reference electrode and a stainless steel block as 
the auxiliary electrode. Amperometric recordings were carried out, where the working electrode was 
set at a potential of + 850 mV vs. Ag|AgCl reference electrode. Control and data collection/processing 
were handled through the CHI1001A software. The stock buffer for the mobile phase comprised of the 
following: 0.1 M sodium acetate, 0.1 M citric acid and 27 μ M disodium ethylene-diamine-tetra-acetate 
(EDTA). This was then buffered to pH 3.0. The mobile phase was prepared with the stock buffer mixed 
with methanol in the ratio of 8:2 (v/v) and degassed after mixing. Standard solutions of 5-HTP, 5-HT, 
tryptophan and 5-HIAA were prepared in 0.1 M perchloric acid (Sigma Aldrich). Each of the standard 
solutions were prepared on the day of analysis and stored at 4 °C prior to injection. A calibration plot 
was obtained for each of the chemicals at a concentration range of 0.01–10 μ M. The peak areas obtained 
from chromatographic analysis of all injected samples were converted to concentrations utilising the cali-
bration responses. The concentration of each chemical was normalized by the total protein content using 
the Bradford method to account for differences in mucosal biomass between samples. Control samples of 
bacteria in Krebs buffer only without mucosal scrapings were used to determine average bacterial protein 
content, which was subtracted from all co-cultured samples.
Measurement of short chain fatty acids from EcN and MG1655. Production of short chain 
fatty acids (SCFA) was measured after growth of E. coli strains with intestinal mucosal scraping under 
co-culture conditions (as described above), and filtration (0.2-μ m-pore-size filter), and used for analysis 
of derivatives SCFA by reversed phase HPLC (RP-HPLC) developed by Schiffels et al.75. Analyses were 
performed using a Waters 2695 Alliance Separation Module, equipped with a quaternary gradient pump, 
column oven autosampler (Kinetex ), and a Waters 2487 Dual Absorbance UV/Vis Detector and a PE 
Nelson 900 series Interface. The data was collected via TotalChrom navigator software (PerkinElmer, 
Shelton, CT). Mobile phase A consisted of 20 mM triethylamine, 20 mM ammonium acetate, adjusted 
to pH 4.7 with formic acid. Mobile phase B was acetonitrile. Total SCFAs were extracted by addition 
of 0.2 g of NaCl and 100 μ L of concentrated HCl to 300 μ L aliquots, followed by 800 μ L of diethyl ether 
containing 35 mM hexanoic acid internal standard. Following centrifugation (1 min at 12,000 g), 200 μ L 
of the obtained ether phase was recovered for analysis, and treated with 200 μ L of oxalyl chloride solution 
[250 mM oxalyl chloride in N,N-dimethyl formamide/acetonitrile 1:100 (v/v)]. Tubes were incubated at 
room temperature for 5 min then 800 μ L of derivatization reagent (50 mM 4-nitrophenol in 500 mM 
pyridine/acetonitrile) was added to produce 4-nitrophenyl esters of SFCAs. After derivatization, 20 μ L of 
each SCFA standard and sample solution were injected onto a C18 column (Fortis 150 mm × 3 mm, 3 μ M; 
Fortis Technologies Ltd, Cheshire, UK) at 40 °C, with detection at λ = 295 nm. The following binary gra-
dient (A%/B%) was applied: 20/80 (hold 1 min) to 0/100 (in 6 min) back to 20/80 (in 5 min, hold 5 min). 
Flow rate was 0.6 mL/min throughout.
Data analysis. Peak areas from chromatograms of neurochemicals were normalised to the protein 
content of the sample. The normalised data were expressed as micromolar concentration of the neuro-
chemical being tested per milligram protein of the mucosal-bacterial sample (μ M mg-1 protein). The 
difference in the baseline to peak current observed when the BDD microelectrode was placed over the 
tissue during amperometry recordings were monitored and the resultant current was converted to con-
centration using a pre-calibrated response to 5-HT. ANOVA was used for comparison between grouped 
samples, assuming populations were Gaussian (H0: means are equal, 95% confidence interval level). 
Whenever H0 was rejected (P < 0.05), the Bonferroni post-test (post-hoc) to correct for multiple com-
parisons was employed. Data were analysed using GraphPad Prism V5.03.
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